IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.

Scheffold, Annika

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. [electronic resource] - Blood 08 2019 - 534-547 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1528-0020

10.1182/blood.2018881029 doi


Animals
Antineoplastic Agents--pharmacology
Cell Line, Tumor
Class Ia Phosphatidylinositol 3-Kinase--genetics
DNA Mutational Analysis
Disease Models, Animal
Drug Resistance, Neoplasm
Humans
Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy
Mice
Mutation
Phosphoinositide-3 Kinase Inhibitors--pharmacology
Receptor, IGF Type 1--genetics
Treatment Outcome
Exome Sequencing
Xenograft Model Antitumor Assays